Sector News

Ferring’s chief science officer to take over as executive board president in January

November 1, 2018
Life sciences

Ferring Pharmaceuticals’ chief operating officer and president of its executive board, Michel Pettigrew, announced that he plans to retire Dec. 31.

Chief Science Officer Per Falk, Ph.D., who oversees the company’s R&D and regulatory activities, will take over the additional role of president of the executive committee starting Jan. 1, 2019.

Pettigrew first joined the Switzerland-based Ferring in 2001 and helped it grow its annual revenues from €345 million (about $390 million at the time) to about €2 billion today ($2.28 billion), making it one of the largest global pharma companies. Before that, he served as vice president of Bristol-Myers Squibb’s oncology division in Europe.

“I wish Per every success in his expanded leadership role,” said Frederik Paulsen, chairman of Ferring’s board of directors. “With his strong scientific and medical background, Per will lead Ferring with the Executive Committee to its next phase of growth and innovation.”

Falk joined Ferring in 2015, and has helped accelerate its focus on the microbiome, as well as its work in a number of external collaborations. He also helped the company acquire Rebiotix and its microbiota restoration therapy platform this past April.

The acquisition’s lead candidate is a non-antibiotic treatment to prevent recurrent C. difficile infections by delivering healthy, live, human-derived microbes to the gut, currently in phase 3 trials. The asset, RBX-2660, has received fast track, breakthrough and orphan drug designations from the FDA.

“This is a long-term investment for us. We see it more as an R&D investment that creates a complete, mature microbiome platform rather than product acquisition from which we are looking to get short-term financial gains,” Falk said at the time. “We will grow from this rather than say it all hinges on the success of the front-runner project.”

Before Ferring, Falk held several executive and leadership roles, including in R&D and regional commercial leadership, during over 12 years at Novo Nordisk.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.